ZVRA Insider Trading

Insider Ownership Percentage: 1.10%
Insider Buying (Last 12 Months): $133,682.25
Insider Selling (Last 12 Months): $0.00

Zevra Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Zevra Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zevra Therapeutics Share Price & Price History

Current Price: $5.80
Price Change: Price Decrease of -0.14 (-2.36%)
As of 03/28/2024 05:00 PM ET

This chart shows the closing price history over time for ZVRA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Zevra Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/6/2023R. Laduane CliftonCFOBuy1,000$4.96$4,960.0015,309View SEC Filing Icon  
9/5/2023John B BodeDirectorBuy10,000$5.13$51,300.0020,000View SEC Filing Icon  
9/5/2023Joshua SchaferEVPBuy500$5.13$2,565.003,500View SEC Filing Icon  
6/23/2023Corey Michael WattonDirectorBuy275$5.95$1,636.251,000View SEC Filing Icon  
6/9/2023Corey Michael WattonDirectorBuy325$5.52$1,794.00725View SEC Filing Icon  
5/30/2023Corey Michael WattonDirectorBuy400$5.11$2,044.00400View SEC Filing Icon  
5/19/2023Joshua SchaferEVPBuy1,000$5.42$5,420.003,000View SEC Filing Icon  
5/18/2023John B BodeDirectorBuy10,000$5.04$50,400.0010,000View SEC Filing Icon  
5/18/2023R. Laduane CliftonCFOBuy2,740$4.95$13,563.0013,742View SEC Filing Icon  
3/17/2023Tamara A SeymourDirectorBuy519$4.82$2,501.58719View SEC Filing Icon  
3/14/2023Joshua SchaferEVPBuy2,000$4.61$9,220.002,000View SEC Filing Icon  
3/10/2023R. Laduane CliftonCFOBuy1,725$4.15$7,158.7511,002View SEC Filing Icon  
3/10/2023Timothy J SangiovanniSVPBuy1,200$4.14$4,968.004,449View SEC Filing Icon  
3/9/2023Matthew R PloosterDirectorBuy11,000$4.20$46,200.0018,500View SEC Filing Icon  
3/9/2023Richard W PascoeCEOBuy10,000$4.20$42,000.0029,973View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Zevra Therapeutics (NASDAQ:ZVRA)

35.03% of Zevra Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ZVRA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Zevra Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
3/11/2024Vanguard Group Inc.1,645,140$10.78M0.0%+2.0%4.542%Search for SEC Filing on Google Icon
3/1/2024Goldman Sachs Group Inc.35,703$0.23M0.0%+17.6%0.099%Search for SEC Filing on Google Icon
2/26/2024Virtu Financial LLC26,966$0.18M0.0%N/A0.074%Search for SEC Filing on Google Icon
2/16/2024Public Employees Retirement System of Ohio5,337$35K0.0%+52.5%0.015%Search for SEC Filing on Google Icon
2/15/2024Barclays PLC49,997$0.33M0.0%+738.2%0.138%Search for SEC Filing on Google Icon
2/15/2024Vanguard Group Inc.1,645,140$10.78M0.0%+2.0%4.542%Search for SEC Filing on Google Icon
2/15/2024Nantahala Capital Management LLC2,453,405$16.07M1.0%+6.3%6.774%Search for SEC Filing on Google Icon
2/14/2024Royal Bank of Canada14,753$97K0.0%+86.7%0.041%Search for SEC Filing on Google Icon
2/13/2024Northern Trust Corp301,066$1.97M0.0%+11.3%0.831%Search for SEC Filing on Google Icon
2/13/2024Tower Research Capital LLC TRC 9,673$63K0.0%+134.3%0.027%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC268,000$1.76M0.0%N/A0.740%Search for SEC Filing on Google Icon
2/13/2024Goldman Sachs Group Inc.35,703$0.23M0.0%+17.6%0.099%Search for SEC Filing on Google Icon
2/12/2024Focus Financial Network Inc. ADV21,500$0.14M0.0%N/A0.059%Search for SEC Filing on Google Icon
2/9/2024UBS Group AG35,110$0.23M0.0%+87.3%0.097%Search for SEC Filing on Google Icon
2/8/2024Janney Montgomery Scott LLC683,431$4.48M0.0%+1.3%1.887%Search for SEC Filing on Google Icon
2/7/2024Dimensional Fund Advisors LP43,605$0.29M0.0%-19.1%0.120%Search for SEC Filing on Google Icon
2/7/2024Jump Financial LLC33,200$0.22M0.0%N/A0.092%Search for SEC Filing on Google Icon
2/6/2024Charles Schwab Investment Management Inc.96,130$0.63M0.0%+6.3%0.265%Search for SEC Filing on Google Icon
2/2/2024Kovack Advisors Inc.141,401$0.93M0.1%+13.9%0.390%Search for SEC Filing on Google Icon
1/30/2024Strs Ohio19,400$0.13M0.0%+151.9%0.054%Search for SEC Filing on Google Icon
1/25/2024International Assets Investment Management LLC6,550$43K0.0%+555.0%0.018%Search for SEC Filing on Google Icon
1/24/2024International Assets Investment Management LLC6,550$43K0.0%+555.0%0.018%Search for SEC Filing on Google Icon
1/12/2024SG Americas Securities LLC20,999$0.14M0.0%+41.7%0.058%Search for SEC Filing on Google Icon
12/18/2023Vanguard Group Inc.1,612,501$7.77M0.0%N/A4.452%Search for SEC Filing on Google Icon
12/6/2023VisionPoint Advisory Group LLC6,860$33K0.0%N/A0.019%Search for SEC Filing on Google Icon
11/30/2023American Century Companies Inc.17,679$85K0.0%N/A0.049%Search for SEC Filing on Google Icon
11/17/2023Jacobs Levy Equity Management Inc.62,575$0.30M0.0%N/A0.173%Search for SEC Filing on Google Icon
11/15/2023The Manufacturers Life Insurance Company 15,779$76K0.0%N/A0.044%Search for SEC Filing on Google Icon
11/15/2023Laurion Capital Management LP31,200$0.15M0.0%N/A0.086%Search for SEC Filing on Google Icon
11/14/2023California State Teachers Retirement System7,508$36K0.0%N/A0.021%Search for SEC Filing on Google Icon
11/13/2023Northern Trust Corp270,442$1.30M0.0%N/A0.747%Search for SEC Filing on Google Icon
11/13/2023Retirement Planning Co of New England Inc.347,402$1.67M0.9%N/A0.959%Search for SEC Filing on Google Icon
11/13/2023Mystic Asset Management Inc.203,283$0.98M0.6%N/A0.561%Search for SEC Filing on Google Icon
11/13/2023LPL Financial LLC19,593$94K0.0%N/A0.054%Search for SEC Filing on Google Icon
11/13/2023Invesco Ltd.13,371$64K0.0%N/A0.037%Search for SEC Filing on Google Icon
11/9/2023Rhumbline Advisers45,721$0.22M0.0%N/A0.135%Search for SEC Filing on Google Icon
11/9/2023Deutsche Bank AG16,052$77K0.0%N/A0.047%Search for SEC Filing on Google Icon
11/9/2023UBS Group AG18,742$90K0.0%N/A0.055%Search for SEC Filing on Google Icon
11/8/2023Charles Schwab Investment Management Inc.90,432$0.44M0.0%N/A0.267%Search for SEC Filing on Google Icon
11/8/2023Janney Montgomery Scott LLC674,369$3.25M0.0%N/A1.988%Search for SEC Filing on Google Icon
11/7/2023Kingsview Wealth Management LLC12,120$58K0.0%N/A0.036%Search for SEC Filing on Google Icon
10/31/2023IFG Advisors LLC12,900$62K0.0%N/A0.038%Search for SEC Filing on Google Icon
10/26/2023Mirae Asset Global Investments Co. Ltd.19,072$92K0.0%N/A0.056%Search for SEC Filing on Google Icon
10/26/2023Strs Ohio7,700$37K0.0%N/A0.023%Search for SEC Filing on Google Icon
10/24/2023Bank of New York Mellon Corp202,773$0.98M0.0%N/A0.598%Search for SEC Filing on Google Icon
10/24/2023Stratos Wealth Partners LTD.70,200$0.34M0.0%N/A0.207%Search for SEC Filing on Google Icon
10/24/2023Raymond James Financial Services Advisors Inc.26,228$0.13M0.0%N/A0.077%Search for SEC Filing on Google Icon
10/23/2023Commonwealth Equity Services LLC10,858$52K0.0%N/A0.032%Search for SEC Filing on Google Icon
10/18/2023Measured Wealth Private Client Group LLC10,000$48K0.0%N/A0.029%Search for SEC Filing on Google Icon
10/16/2023City State Bank14,224$69K0.0%N/A0.042%Search for SEC Filing on Google Icon
10/13/2023SG Americas Securities LLC14,824$71K0.0%N/A0.044%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Zevra Therapeutics logo
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Read More on Zevra Therapeutics

Today's Range

Now: $5.80
Low: $5.74
High: $6.35

50 Day Range

MA: $6.17
Low: $5.64
High: $7.08

52 Week Range

Now: $5.80
Low: $3.89
High: $7.28

Volume

317,512 shs

Average Volume

250,511 shs

Market Capitalization

$210.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.82

Who are the company insiders with the largest holdings of Zevra Therapeutics?

Zevra Therapeutics' top insider investors include:
  1. Richard W Pascoe (CEO)
  2. John B Bode (Director)
  3. Matthew R Plooster (Director)
  4. R Laduane Clifton (CFO)
  5. Timothy J Sangiovanni (SVP)
  6. Joshua Schafer (EVP)
  7. Corey Michael Watton (Director)
  8. Tamara A Seymour (Director)
Learn More about top insider investors at Zevra Therapeutics.

Who are the major institutional investors of Zevra Therapeutics?

Zevra Therapeutics' top institutional shareholders include:
  1. Nantahala Capital Management LLC — 6.77%
  2. Vanguard Group Inc. — 4.54%
  3. Vanguard Group Inc. — 4.54%
  4. Janney Montgomery Scott LLC — 1.89%
  5. Northern Trust Corp — 0.83%
  6. Armistice Capital LLC — 0.74%
Learn More about top institutional investors of Zevra Therapeutics stock.

Which institutional investors are selling Zevra Therapeutics stock?

Within the previous quarter, ZVRA stock was sold by these institutional investors:
  1. Dimensional Fund Advisors LP
  2. GTS Securities LLC

Which institutional investors are buying Zevra Therapeutics stock?

Within the previous quarter, ZVRA stock was acquired by institutional investors including:
  1. Armistice Capital LLC
  2. Simplex Trading LLC
  3. Nantahala Capital Management LLC
  4. Barclays PLC
  5. Jump Financial LLC
  6. Vanguard Group Inc.
  7. Vanguard Group Inc.
  8. Northern Trust Corp
During the previous year, these company insiders have bought Zevra Therapeutics stock:
  1. Richard W Pascoe (CEO)
  2. John B Bode (Director)
  3. Matthew R Plooster (Director)
  4. R Laduane Clifton (CFO)
  5. Timothy J Sangiovanni (SVP)
  6. Joshua Schafer (EVP)
  7. Corey Michael Watton (Director)
  8. Tamara A Seymour (Director)
Learn More investors buying Zevra Therapeutics stock.